Prediction markets have driven a lot of attention. These platforms allow prospective investors and speculators to trade on the outcomes of real-world events ranging from sporting events to elections to even weather-related events. One of the more prominent prediction market has become Kalshi. Although some analysts worry it blurs the line between investing and gambling , it has become highly succe...
Prediction markets have driven a lot of attention. These platforms allow prospective investors and speculators to trade on the outcomes of real-world events ranging from sporting events to elections to even weather-related events. One of the more prominent prediction market has become Kalshi. Although some analysts worry it blurs the line between investing and gambling , it has become highly successful. With that, its performance has naturally led to questions as to whether the company will launch an IPO and begin trading on the stock market in 2026. Continue reading
Novo Nordisk A/S ’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. Among investors, news of CagriSema’s poor showing against Eli Lilly & Co.’s Zepbound sparked calls for a radical shift. Novo shares plummet...
Novo Nordisk A/S ’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. Among investors, news of CagriSema’s poor showing against Eli Lilly & Co.’s Zepbound sparked calls for a radical shift. Novo shares plummeted 16.5% in the latest dramatic fall for a stock that is down about 61% in the past year. Some investors are now leaning on Novo CEO Mike Doustdar to diversify away from diabetes and obesity, the twin fields that have defined the Danish drugmaker for the past 30 years. “They just need another leg,” said Markus Manns, portfolio manager at Frankfurt-based Union Investment and a Novo investor. “Obesity and diabetes — it’s too risky to bet the entire company on these two franchises.” Watch More: Novo New Obesity Shot Falls Short of Lilly Rival Expanding its repertoire would reduce Novo’s risk as its blockbuster drugs Ozempic and Wegovy brace for generic competition in the US market early next decade, according to analysts and investors. Still, such a pivot would be a significant move for Novo, which established the modern obesity market and has been a leader in diabetes medication since its founding some 120 years ago. “We want to retain and sustain and grow our leadership in diabetes and obesity and be the best in world within those two areas,” Doustdar said earlier this month at a presentation of the company’s full-year results. Although Novo’s Wegovy was first to market among the current generation of powerful weight-loss drugs, it has struggled to keep up with Zepbound. By the time that drug beat Wegovy in a head-to-head obesity study last year, Novo had already pinned its hopes on CagriSema as the next-generation medicine that would cement its dominance. But the study published today showed that CagriSema’s 20.2% weight-loss for people treated with a standard dose failed t...
Ontario Municipal Employees Retirement System returned 6% last year after gains from stock holdings and private credit more than offset private equity losses and a weak dollar. That brings its net assets to C$145.2 billion ($106 billion) last year, up from C$138.2 billion in 2024, the pension said in a statement Monday. “Volatile currency markets create challenges for many investors who invest abr...
Ontario Municipal Employees Retirement System returned 6% last year after gains from stock holdings and private credit more than offset private equity losses and a weak dollar. That brings its net assets to C$145.2 billion ($106 billion) last year, up from C$138.2 billion in 2024, the pension said in a statement Monday. “Volatile currency markets create challenges for many investors who invest abroad,” Chief Executive Officer Blake Hutcheson said in the statement, adding that decisions to hedge currencies helped “limit the foreign exchange impact on our results to negative 1.3%, driven mainly by the strong decline in the value of the US dollar.” Public equity holdings gained 12.3% last year, while private credit and infrastructure delivered 8.3% and 6% returns, respectively. Investments in private equity lost 2.5%, compared with a 9.5% gain in 2024. The pension plan has revamped its private equity group over the past two years, including hiring a new global head, halting direct buyouts in Europe and cutting a team focused on the asset class in Asia. Read More: Canada’s Stewards of $1.2 Trillion Money Pot Revamp PE Model Earlier this month the private equity arm agreed to sell specialty care management company Paradigm to Patient Square Capital , and in December CBI Health , one of Omers’ longstanding portfolio companies, agreed to sell its home-care business to Extendicare Inc. in December. Omers said that it is “well-positioned” to invest in Canada and that it’s seeking “near-term opportunities in Canada that will support both our objectives and the country’s growth.”
Viktor Orbán’s government blocks fresh economic measures against Russia on eve of war’s fourth anniversary Europe live – latest updates European leaders have accused Hungary of sabotaging support for Ukraine on the eve of the fourth anniversary of Vladimir Putin’s full-scale invasion, after a defiant Budapest blocked fresh economic measures against Moscow. Germany, France and other EU states faile...
Viktor Orbán’s government blocks fresh economic measures against Russia on eve of war’s fourth anniversary Europe live – latest updates European leaders have accused Hungary of sabotaging support for Ukraine on the eve of the fourth anniversary of Vladimir Putin’s full-scale invasion, after a defiant Budapest blocked fresh economic measures against Moscow. Germany, France and other EU states failed to persuade Viktor Orbán’s government on Monday to approve the latest EU sanctions package and a loan meant to help Kyiv meet its military and financial needs. Poland’s prime minister, Donald Tusk, described Hungary’s actions as “political sabotage”. Continue reading...
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Highly awaited quarterly results from Nvidia and two key software stocks will test important levels in the market this week, Jay Woods says. Woods, chief market strategist at Freedom Capital Markets, is looking to see Nvidia stock move steadily h...
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Highly awaited quarterly results from Nvidia and two key software stocks will test important levels in the market this week, Jay Woods says. Woods, chief market strategist at Freedom Capital Markets, is looking to see Nvidia stock move steadily higher on the back of its fiscal fourth-quarter earnings due after market close Wednesday. That's because of some choppy post-earnings moves in tech recently, Woods said, noting both Meta and Palantir shares declined even after the company's had great results. Even more important to consider is the effect of Nvidia's report on the S & P 500 , given its 7% stake in the broader market, Woods said. The S & P 500's repeated tests of the 7,000 level are putting a focus to the index's 100-day moving average at 6,822, he said. "Watch how [Nvidia] closes on Thursday. ... We want to see it open strong, stay strong. If not, if it pulls back, watch the 200-day moving average, this $173 area in Nvidia," Woods said. "If it breaks it, that would be a tell for this entire market. We could get a big flush out to 6,600 in the S & P 500 and Nvidia could go back to $150 over the next several months. So, very critical to watch the price action in Nvidia." Nvidia shares are up 2% year to date. The stock is outperforming its "Magnificent Seven" peers in a weak year so far for the group. NVDA 1Y mountain Nvidia stock performance over the past year. Results from Salesforce and Snowflake , also due Wednesday, are another key event for the market this week. Investors will be gauging just how disruptive AI has become to the software industry from the companies' guidance, Woods said. "These stocks need a relief rally and watch their recent lows. They need to hold. If these stocks can bounce, the question is, is this relief or is this something that has changed? Irregardless, we need these stocks to com...
Reform’s ‘shadow home secretary’, Zia Yusuf, launches tirade of misery that sounded more hardline and deranged as it went It was only last week that Nigel Farage declared he was no longer a one-man band with the announcement of a handful of key appointments. Though that does not mean his “Mini-Mes” can yet be trusted to be allowed out on their own. Baby steps and all that. Nige would rather die th...
Reform’s ‘shadow home secretary’, Zia Yusuf, launches tirade of misery that sounded more hardline and deranged as it went It was only last week that Nigel Farage declared he was no longer a one-man band with the announcement of a handful of key appointments. Though that does not mean his “Mini-Mes” can yet be trusted to be allowed out on their own. Baby steps and all that. Nige would rather die than let someone else hog all the limelight. It’s not that his team would screw up. That would be just fine. The worry is always that they might do too well. Might reckon they could live without him. Farage needs to watch them all like a hawk. Continue reading...
GeneDx ( WGS ) is up ~3% in Monday trading after reporting Q4 2025 results that beat on both lines and reiterating 2026 revenue guidance. The genetic testing provider sees revenue this year of $540M-$555M. The consensus is $542.99M. GeneDx was helped in the quarter by a 34.3% year-over-year increase in exome and genome test result volume to 27,761. TD Cowen's Dan Brennan, who rates GeneDx a buy wi...
GeneDx ( WGS ) is up ~3% in Monday trading after reporting Q4 2025 results that beat on both lines and reiterating 2026 revenue guidance. The genetic testing provider sees revenue this year of $540M-$555M. The consensus is $542.99M. GeneDx was helped in the quarter by a 34.3% year-over-year increase in exome and genome test result volume to 27,761. TD Cowen's Dan Brennan, who rates GeneDx a buy with a $165 price target (~101% upside based on Feb. 20 close), said that the company's exome and genome volume guidance "looks to set a high bar" at 33%-35% growth. He added where there is "room for upside" in the stock. Canaccord's Kyle Mikson, who has a buy rating and a $170 price target (~170% upside), noted he would be "further encouraged" if testing volume accelerated beyond expectations. More on GeneDx Holdings GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force GeneDx Holdings Non-GAAP EPS of $0.18 beats by $0.06, revenue of $121M beats by $0.56M
Harry Brook’s side have been unconvincing against the turning ball and will face a team that has an attack packed with spinning options After four wins in five games, and now just one away from sealing a place in the semi‑finals, it is hard to describe England’s progress through the World Cup as ugly. But it hasn’t been straightforward. Like an inverted swan, everyone can see them struggling – yet...
Harry Brook’s side have been unconvincing against the turning ball and will face a team that has an attack packed with spinning options After four wins in five games, and now just one away from sealing a place in the semi‑finals, it is hard to describe England’s progress through the World Cup as ugly. But it hasn’t been straightforward. Like an inverted swan, everyone can see them struggling – yet somehow their progress has been, up to this point, serene. There are no bonus points available for artistic merit and to win tournaments it is necessary only to be, at each stage, slightly better than your opponents. Australia’s T20 champions of 2021, for example, were a side few considered the best in that competition – and were notably annihilated by England in the group stages – until Aaron Finch raised the trophy in Dubai. Continue reading...
LeoPatrizi/E+ via Getty Images I'm revising SK Telecom Co., Ltd.'s ( SKM ) (017670.KS) rating from "Hold" to "Buy." Catalysts relating to dividend restoration and the Anthropic ( ANTHRO ) stake monetization justify my bullish view of this name. My December 11, 2025, article touched on the negative outlook for its shareholder returns and the "Data Center/DC" division's solid prospects. Anticipating...
LeoPatrizi/E+ via Getty Images I'm revising SK Telecom Co., Ltd.'s ( SKM ) (017670.KS) rating from "Hold" to "Buy." Catalysts relating to dividend restoration and the Anthropic ( ANTHRO ) stake monetization justify my bullish view of this name. My December 11, 2025, article touched on the negative outlook for its shareholder returns and the "Data Center/DC" division's solid prospects. Anticipating Payout Reinstatement SKM's CFO emphasized at the FY2025 briefing in early February that "we will do our best to return to the previous dividend payout levels" in '26. The group suspended its cash distributions for 3Q/4Q25. This resulted in the full-year payment dropping 53% to ₩1,660/share. I noted in the Dec '25 piece, "It seems unlikely that the payout will be restored in Q4." My reasoning was that some "clients impacted by the (Apr 2025) cyberattack" could have "traded down to lower-priced wireless plans" after having "their data quota expanded by 50,000MB for free." Moving forward, my bet is on the firm honoring its commitment to returning capital to stockholders again. In its investor slides , SKM attributed the two-fifths drop in last year's "Operating Profit/OP" to expenses regarding the "cybersecurity incident" and "early retirement program." My calculations point to ₩1 trillion of FY25 charges pertaining to rightsizing efforts and hacking-related penalties. These should be non-recurring this year. A leaner workforce will likely translate into lower operating costs, too. Separately, my end-of-2025 write-up highlighted that "SKM's rivals KT Corporation ( KT ) and LG Uplus also suffered from data breaches." Similar woes at its rivals have already boosted the former's performance in early '26. "The Korea Times" reported in the prior week that around 0.3 million subscribers "switched to SK Telecom" from LG/KT in Jan. Also, I believe SKM's DC arm will continue to do well in the near term. Its DC-related topline surged by +59% and +34% for 4Q2025 and FY2025, respectively...
KanawatTH Broadcom ( AVGO ) is still considered the “best-in-class” in the custom application specific integrated circuit market, but Marvell ( MRVL ), Arm ( ARM ), and perhaps surprisingly, Qualcomm ( QCOM ), are making inroads, Evercore said. “AVGO mentioned as both best-in-class in IP and execution as well as the priciest,” analyst Mark Lipacis wrote in a note to clients. “MRVL is viewed as hig...
KanawatTH Broadcom ( AVGO ) is still considered the “best-in-class” in the custom application specific integrated circuit market, but Marvell ( MRVL ), Arm ( ARM ), and perhaps surprisingly, Qualcomm ( QCOM ), are making inroads, Evercore said. “AVGO mentioned as both best-in-class in IP and execution as well as the priciest,” analyst Mark Lipacis wrote in a note to clients. “MRVL is viewed as highly capable and believed to have AWS’s Trainium 4, some of Trainium 3 and MSFT’s Maia. ARM ( ARM ) is also competing aggressively for CPU, DPU, and XPU programs, and QCOM is viewed as making progress in the AI-ASIC market, with its chips running small language models in Meta’s Ray Bans and other AI wearables.” Delving deeper, Broadcom is considered the “premium, one-stop shop” for ASICs, given that it has leading intellectual property in both analog and digital and is the best at execution, Lipacis added. The company also has strength in its high-speed I/O offering, and its experience working with Taiwan Semiconductor ( TSM ) and its deep, technical bench are both assets, Lipacis explained. Conversely, its high cost (margins are 10% higher than Marvell) and its lack of flexibility are considered negatives, he added. For Marvell, its flexibility compared to Broadcom is considered a major strength, Lipacis added, notable, given its intellectual property assets are not as strong as Broadcom's. However, it does have advantages over its Taiwanese competitors, notably its “superior front-end circuit design capabilities,” Lipacis explained. It also has two major customers—Amazon ( AMZN ) and Microsoft ( MSFT )—with its Amazon work improving, as the defect rate may have been cut by 65% when it took over work on Trainium 2. It is also seen as “indispensable” for Microsoft's Maia program. (Microsoft released a new Maia AI accelerator last month.) Arm, on the other hand, is working to “aggressively” compete for development programs at the major hyperscalers and show off its capabiliti...
Anthropic PBC said three leading artificial intelligence developers in China worked to “illicitly extract” results from its AI models to bolster the capabilities of rival products, adding to growing concerns in the US about Chinese firms improperly gaining an edge. The San Francisco-based company said DeepSeek , MiniMax Group Inc. and Moonshot violated its terms of service by generating more than ...
Anthropic PBC said three leading artificial intelligence developers in China worked to “illicitly extract” results from its AI models to bolster the capabilities of rival products, adding to growing concerns in the US about Chinese firms improperly gaining an edge. The San Francisco-based company said DeepSeek , MiniMax Group Inc. and Moonshot violated its terms of service by generating more than 16 million exchanges in total with its Claude models using thousands of fraudulent accounts. With this tactic, known as distillation, Chinese AI labs can rapidly improve their models by training them on the outputs from more powerful systems, Anthropic said. Anthropic rival OpenAI warned US lawmakers earlier this month that DeepSeek had used distillation techniques as part of “ongoing efforts to free-ride on the capabilities developed by OpenAI and other US frontier labs.” Other US officials, including White House AI czar David Sacks , have also expressed concerns that DeepSeek used this method. “These campaigns are growing in intensity and sophistication,” Anthropic said in a blog post on Monday. “The window to act is narrow, and the threat extends beyond any single company or region.” Representatives for DeepSeek, MiniMax and Moonshot did not respond to requests for comment after normal business hours. DeepSeek upended the AI landscape a year ago with the release of R1, a competitive model purportedly built at a fraction of the cost of leading US alternatives. Since then, China has flooded the market with a wave of affordable text, video and image models. That has threatened to undercut adoption of AI software from US firms, making it harder to monetize the technology. MiniMax made its public market debut in January. Moonshot, meanwhile, is targeting a $10 billion valuation in a new financing round. Anthropic said the three firms each used “fraudulent accounts and proxy services to access Claude at scale while evading detection.” Proxy networks can be used to provide a ...